Skip to Main Content

Medical pioneers Carl June, Bruce Levine, and Drew Weissman have teamed up to launch a new biotech that hopes to use the industry’s buzziest technologies to boost the beleaguered cell therapy field.

Their new venture, Capstan Therapeutics, launched Wednesday with a combined $165 million in seed and Series A financing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment